Inhibiting VEGF pathways has been demonstrated to reduce tumor growth; for instance, the anti-HER2 antibody trastuzumab effectively diminishes tumor cell proliferation and decreases VEGF expression [89]. Here, ERBB2 is linked to neoplasm.